Letters to the Editor

Do Vaginal Estrogens Increase Endometrial Proliferation Risk?


Am Fam Physician. 2011 Aug 15;84(4):354-355.

Original Article: Counseling Patients About Hormone Therapy and Alternatives for Menopausal Symptoms

Issue Date: October 1, 2010

Available at: https://www.aafp.org/afp/2010/1001/p801.html

to the editor: I am concerned about a discrepancy in this article on the risk of endometrial proliferation with use of vaginal estrogens. In the Vulvovaginal Symptoms section, it says: “Physicians should reassure patients that vaginal estrogen does not cause endometrial proliferation and that adding a progestogen for endometrial protection is not necessary.” However, the next paragraph states: “Vaginal administration of estradiol may cause an increase in serum estradiol levels in some patients, but data are lacking about the long-term risks of breast cancer, [venous thromboembolism], or endometrial proliferation for patients who use low-dose vaginal estrogen therapy.”

I would like clarification about whether data on the risks of endometrial proliferation with vaginal estrogen use are unclear or not.

Author disclosure: No relevant financial affiliations to disclose.

in reply: Dr. Andreini asks about the risk of endometrial proliferation with use of vaginal (topical) estrogen therapy for vulvovaginal symptoms. Patients using recommended doses of intravaginal estrogen to treat vulvovaginal atrophy have a very low risk of endometrial proliferation or hyperplasia. Numerous studies have compared the effectiveness and safety of various local estrogen formulations, including effects on the endometrium. However, it can be hard to evaluate these studies. Some use endometrial biopsy results, a robust indicator of proliferation or hyperplasia, whereas others use arguably less definitive indicators, such as bleeding after progestogen challenge testing or endometrial thickness measured by transvaginal sonography.

Data are available that used endometrial biopsy to assess the safety of local estrogen therapy. A Cochrane review of 19 trials found a nonsignificant 2 percent incidence of simple hyperplasia (vaginal ring versus cream) and a 4 percent incidence of hyperplasia (one simple, one complex) when conjugated equine estrogen cream (Premarin) was compared with an estradiol tablet.1 Recent year-long studies of vaginal conjugated estrogen cream (423 patients) and low-dose estradiol vaginal tablets (292 patients) revealed no cases of endometrial hyperplasia or cancer as determined by endometrial biopsy.2,3 These reassuring data have led several organizations to state that patients using only local estrogen do not need cotherapy with progestogens for endometrial protection.4,5 However, as stated in our review, it is unknown if endometrial proliferation, hyperplasia, or malignancy can occur after long-term treatment (many years) with local estrogen.

Patients considering local estrogen therapy should be told that short-term data are reassuring that endometrial proliferation, hyperplasia, or malignancy appears to be rare (and nonexistent in several newer studies), but we recommend that they return for evaluation if unexpected vaginal bleeding occurs. We thank Dr. Andreini for the interest in our review.

Author disclosure: No relevant financial affiliations to disclose.


show all references

1. Suckling J, et al. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev. 2006;(4):CD001500....

2. Bachmann G, et al. Efficacy and safety of low-dose regimens of conjugated estrogens cream administered vaginally. Menopause. 2009;16(4):719–727.

3. Ulrich LS, et al. VAG-1748 trial investigators. Endometrial safety of ultra-low-dose Vagifem 10 microg in postmenopausal women with vaginal atrophy. Climacteric. 2010;13(3):228–237.

4. Estrogen and progestogen use in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause. 2010;17(2):242–255.

5. Reid RL, et al. Society of Obstetricians and Gynaecologists of Canada. Menopause and osteoporosis update 2009. J Obstet Gynaecol Can. 2009;31:(suppl 1):S1–48.

Send letters to afplet@aafp.org, or 11400 Tomahawk Creek Pkwy., Leawood, KS 66211-2680. Include your complete address, e-mail address, and telephone number. Letters should be fewer than 400 words and limited to six references, one table or figure, and three authors.

Letters submitted for publication in AFP must not be submitted to any other publication. Possible conflicts of interest must be disclosed at time of submission. Submission of a letter will be construed as granting the AAFP permission to publish the letter in any of its publications in any form. The editors may edit letters to meet style and space requirements.

This series is coordinated by Kenny Lin, MD, MPH, Associate Deputy Editor for AFP Online.



Copyright © 2011 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact afpserv@aafp.org for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions


May 2022

Access the latest issue of American Family Physician

Read the Issue

Email Alerts

Don't miss a single issue. Sign up for the free AFP email table of contents.

Sign Up Now

Navigate this Article